...
首页> 外文期刊>Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA >Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study.
【24h】

Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study.

机译:骨吸收标记物是否可以增加骨矿物质密度和超声足跟测量,以预测老年妇女的髋部骨折? EPIDOS前瞻性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

We have previously shown that hip bone mineral density (BMD), heel broadband ultrasound attenuation (BUA) and bone resorption markers are independent predictors of hip fracture in elderly women. We investigated whether a combination of these three parameters could improve the predictive value of a single test in a nested case-control analysis (75 hip fractures and 228 age-matched controls) of the EPIDOS prospective study comprising 7598 healthy women 75 years of age and older followed prospectively for a mean 22 months. At baseline, prior fracture, femoral neck BMD by dual-energy X-ray absorptiometry (DXA), heel BUA and urinary type I collagen C-telopeptide breakdown products (CTX) were assessed. The area under the receiver operating characteristic curve was significant for the three diagnostic tests, heel BUA being the best single predictor. The added value of urinary CTX to either BMD or BUA depends on the cutoff point chosen to define patients at risk and on the therapeutic strategy that is considered. Defining patients at risk as those with low BMD (or low BUA) or high CTX resulted in a significant increase in the sensitivity compared with BMD or BUA alone--a strategy that could be applied when a broad treatment is considered. However, this increased sensitivity was also obtained simply by increasing the BMD and BUA cutoffs, suggesting that a combination of CTX with BMD/BUA is not useful for that type of treatment strategy. Conversely, defining patients at risk as those with both low BMD and high CTX increases the specificity (88% vs 78%) with a similar number of hip fracture patients being identified (30% vs 32%)--a combination that could be useful when the strategy is to target treatment to a subset of high-risk patients. This strategy appears to be more cost-effective than bone mass measurement alone as indicated by the 37% fewer patients who need to be treated to avoid one fracture per year. If DXA or ultrasound is not available, the combination of a bone resorption marker with a history of any type of fracture after the age of 50 years gave a predictive value similar to that obtained with femoral neck BMD or heel BUA alone, for both types of treatment strategy. We conclude that the combination of urinary CTX with hip BMD could be useful for the identification of elderly women at high risk for hip fracture, resulting in higher specificity for a given sensitivity threshold than BMD measurement alone. If DXA is not available, the combination of history of fracture and urinary CTX performs as well as hip BMD to assess hip fracture risk in elderly women.
机译:先前我们已经表明,髋骨矿物质密度(BMD),足跟宽带超声衰减(BUA)和骨吸收标记物是老年妇女髋部骨折的独立预测因子。我们调查了这三个参数的组合是否可以提高一项单项测试在EPIDOS前瞻性研究的嵌套病例对照分析(75例髋部骨折和228例年龄匹配的对照)中的预测价值,该研究包括7598名75岁以上的健康女性和年龄较大的人平均预期随访22个月。在基线时,先行骨折,通过双能X线骨密度仪(DXA),足跟BUA和I型尿胶原C端肽分解产物(CTX)评估股骨颈BMD。在三个诊断测试中,接收器工作特性曲线下方的面积非常重要,脚跟BUA是最佳的单个预测指标。尿CTX对BMD或BUA的附加价值取决于为界定高危患者所选择的临界点以及所考虑的治疗策略。与仅BMD或BUA相比,将风险定义为低BMD(或低BUA)或CTX高的患者会导致敏感性显着提高-当考虑广泛治疗时,可以应用该策略。但是,这种敏感性的提高也可以通过简单地增加BMD和BUA截止值来获得,这表明CTX与BMD / BUA的组合不适用于该类型的治疗策略。相反,将高风险BTX和低CTX的患者定义为高风险患者,则特异性会提高(88%对78%),同时发现的髋部骨折患者数量相似(30%对32%),这可能是有用的组合当策略是针对高危患者的子集时。这种策略似乎比仅测量骨量更具成本效益,因为每年需要治疗以避免骨折的患者减少了37%。如果没有DXA或超声检查,则两种类型的骨吸收标记物与50岁以后有任何类型骨折史的组合的预测值类似于单独使用股骨颈BMD或足跟BUA获得的预测值。治疗策略。我们得出的结论是,尿液CTX与髋部BMD的结合可用于识别高风险髋部骨折的老年妇女,因此,对于给定的灵敏度阈值,比单独进行BMD测量具有更高的特异性。如果没有DXA,则结合骨折史和尿液CTX的表现与评估老年人髋部骨折风险的髋部BMD一样好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号